13 August 2018
Visiongain has launched a new pharma report Forecasts By Product (Spinal Cord Stimulators, Deep Brain Stimulators, Vagus Nerve Stimulators, Sacral Nerve Stimulators, Cortical Stimulators and Others), By Application (Epilepsy, Pain Management, Hearing Loss, Incontinence, Gastroparesis, Parkinson’s Disease and Others) and Geography
The prevalence rates of the spectrum of neurological disorders have been increased significantly in many countries across the globe. According to the Federal Interagency Forum on Aging-Related Statistics, around 35.8% of those 85 or older have moderate or severe memory impairment. Persons 85 years and older are the fastest growing segment of the population. In the U.S., around 1.2 million people aged 18 years and older who are diagnosed annually with adult onset brain disease/disorders.
Neurostimulation is an advanced treatment which helps to reduce certain types of chronic pain or manage neurological conditions. Neurostimulation devices are surgically implanted in the body of the patient and function through thin wires or leads which help them find relief from chronic pain or other neurological conditions.
The lead Visiongain report analyst for this report commented “The risk of chronic and infectious diseases increases with age. Among the geriatric population, the chronic diseases prevalence rate is 64/1,000 persons. The trend of the current rapid rise in elderly population is observed in many regions globally, which is expected to increase the number of patients suffering from chronic diseases such as epilepsy, consequently increasing the demand for various medical devices required for various procedures.”
Thus, with increasing incidence of neurological diseases, the demand for neurostimulation devices is expected to increase significantly in the next few years.
Leading companies who are active in the Neurostimulation market and are featured in the report include Advanced Bionics, Boston Scientific Corporation, Cochlear ltd, Cyberonics, Medtronic Neuronetics Inc, Nervo Corp., Cogentic Medical Inc, St Jude Medical and NDI Medical.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain anticipates that the global precision medicine market is projected to witness a CAGR of 12% over the forecast period from 2020 to 2030. The global precision medicine market is anticipated to surpass US$ 67 billion in 2020 and is further projected to surpass US$ 200 billion in 2030.
27 May 2020
The global colon targeting drug delivery market is projected to grow at a CAGR of 8.07% in the first half of the forecast period. Visiongain anticipate that the global market will witness a CAGR of 9.23% during the forecast period 2020 to 2030.
27 May 2020
The automation in biopharma industry market is estimated to grow at a CAGR of 4.3% over the forecast period.
22 May 2020
The global erectile dysfunction is in a transition phase as the majority of the consumers are shifting from traditional pharmaceuticals to herbal-based products pertaining to lesser side effects and positive perception of natural products amongst the society. Visiongain understands this market to be dynamic, with a large number of players to enter the market.”